DK0948614T3 - Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme - Google Patents
Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdommeInfo
- Publication number
- DK0948614T3 DK0948614T3 DK97954089T DK97954089T DK0948614T3 DK 0948614 T3 DK0948614 T3 DK 0948614T3 DK 97954089 T DK97954089 T DK 97954089T DK 97954089 T DK97954089 T DK 97954089T DK 0948614 T3 DK0948614 T3 DK 0948614T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunomodulation
- treatment
- malignancies
- autoimmune diseases
- expression vectors
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 230000036210 malignancy Effects 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3214596P | 1996-12-09 | 1996-12-09 | |
| US08/982,272 US7070771B1 (en) | 1996-12-09 | 1997-12-01 | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| PCT/US1997/022740 WO1998026061A2 (en) | 1996-12-09 | 1997-12-08 | Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0948614T3 true DK0948614T3 (da) | 2009-05-11 |
Family
ID=26708033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97954089T DK0948614T3 (da) | 1996-12-09 | 1997-12-08 | Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7070771B1 (enExample) |
| EP (4) | EP0948614B1 (enExample) |
| JP (1) | JP4015201B2 (enExample) |
| CN (1) | CN1221662C (enExample) |
| AT (2) | ATE420956T1 (enExample) |
| AU (1) | AU5795798A (enExample) |
| BR (1) | BR9714004A (enExample) |
| CA (2) | CA2274498C (enExample) |
| DE (1) | DE69739220D1 (enExample) |
| DK (1) | DK0948614T3 (enExample) |
| ES (1) | ES2321246T3 (enExample) |
| IL (3) | IL130247A0 (enExample) |
| NO (2) | NO327411B1 (enExample) |
| NZ (1) | NZ336092A (enExample) |
| PT (1) | PT948614E (enExample) |
| WO (1) | WO1998026061A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| WO2000063395A1 (en) * | 1999-04-16 | 2000-10-26 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| GB9917180D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Sheffield | Cell surface receptor |
| GB0025307D0 (en) * | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| AU2002221780A1 (en) * | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| US20050214311A1 (en) * | 2002-02-25 | 2005-09-29 | Screaton Gavin R | Novel complexes for inducing an immune response |
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| WO2008109825A2 (en) * | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| US20100050276A1 (en) * | 2008-08-22 | 2010-02-25 | Brown University | Transgenic non-human animal models of apoptosis-mediated conditions |
| EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| SI2908865T1 (sl) * | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
| WO2015148879A1 (en) * | 2014-03-27 | 2015-10-01 | The Regents Of The University Of Michigan | Cancer immunotherapy compositions and methods |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN105567679B (zh) * | 2014-10-10 | 2019-07-05 | 深圳市北科生物科技有限公司 | 可分泌型trail蛋白构建物和表达载体 |
| WO2017079297A1 (en) | 2015-11-02 | 2017-05-11 | Memgen Llc | Methods for treatment of cancer |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| WO2018191369A1 (en) | 2017-04-12 | 2018-10-18 | Memgen, Llc | Methods of cd40 and toll like receptor immune activation |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN112725379B (zh) * | 2021-01-27 | 2024-08-13 | 上海南方模式生物科技股份有限公司 | 人源化cd40基因改造动物模型的构建方法及应用 |
| US11585330B1 (en) * | 2021-09-29 | 2023-02-21 | Halliburton Energy Services, Inc. | Flow control for geothermal well |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0251037B1 (en) | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
| EP0317641B1 (en) | 1987-05-29 | 1993-03-17 | Sagami Chemical Research Center | Fused protein containing lymphotoxin |
| WO1991002540A1 (en) | 1989-08-16 | 1991-03-07 | Cetus Corporation | Compositions for the inhibition of protein hormone formation and uses thereof |
| US5519119A (en) | 1990-09-21 | 1996-05-21 | Ishihara Sangyo Kaisha Ltd. | Muteins of TNF pharmaceutical compositions and a method of making |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| WO1993008207A1 (en) | 1991-10-25 | 1993-04-29 | Immunex Corporation | Novel cytokine |
| DE69333027T2 (de) | 1992-03-30 | 2004-05-06 | Immunex Corp., Seattle | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält |
| CZ283533B6 (cs) | 1992-04-02 | 1998-04-15 | F. Hoffmann-La Roche Ag | TNF - muteiny a způsob jejich výroby |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| EP0656947A1 (en) | 1992-08-21 | 1995-06-14 | Schering Corporation | Human interleukin-13 |
| WO1994004570A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| DE69433399T2 (de) | 1993-01-22 | 2004-10-14 | Immunex Corp., Seattle | Detektion und behandlung von mutationen in einem gen für einen cd40-liganden |
| JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Ｃｄ４０リガンド遺伝子の突然変異の検出および治療 |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| WO1995018819A1 (en) | 1994-01-07 | 1995-07-13 | Immunex Corporation | Ligand that binds fas antigen |
| MX9605088A (es) | 1994-04-28 | 1997-08-30 | Boehringer Ingelheim Pharma | Metodos para proliferar y diferenciar celulas b y sus usos. |
| US5606023A (en) | 1994-05-24 | 1997-02-25 | Thomas Jefferson University | Mutant tumor necrosis factor proteins |
| US5759536A (en) | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
| JPH09508140A (ja) | 1994-07-22 | 1997-08-19 | エフ・ホフマン−ラ ロシュ アーゲー | キメラｔｎｆ結合タンパク質を含有する医薬組成物 |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US5888764A (en) * | 1995-01-20 | 1999-03-30 | Uab Research Foundation | Human fas gene promoter region |
| US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| US6016832A (en) * | 1997-04-16 | 2000-01-25 | Woodward Governor Company | Valve for controlling gas mass flow |
| DE69841548D1 (de) | 1997-09-17 | 2010-04-22 | Mochida Pharm Co Ltd | Fas-liganden derivate |
| US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
-
1997
- 1997-12-01 US US08/982,272 patent/US7070771B1/en not_active Expired - Fee Related
- 1997-12-08 EP EP97954089A patent/EP0948614B1/en not_active Expired - Lifetime
- 1997-12-08 ES ES97954089T patent/ES2321246T3/es not_active Expired - Lifetime
- 1997-12-08 JP JP52695698A patent/JP4015201B2/ja not_active Expired - Fee Related
- 1997-12-08 CA CA2274498A patent/CA2274498C/en not_active Expired - Fee Related
- 1997-12-08 BR BR9714004-0A patent/BR9714004A/pt not_active IP Right Cessation
- 1997-12-08 AU AU57957/98A patent/AU5795798A/en not_active Abandoned
- 1997-12-08 DK DK97954089T patent/DK0948614T3/da active
- 1997-12-08 NZ NZ336092A patent/NZ336092A/en not_active IP Right Cessation
- 1997-12-08 WO PCT/US1997/022740 patent/WO1998026061A2/en not_active Ceased
- 1997-12-08 IL IL13024797A patent/IL130247A0/xx active IP Right Grant
- 1997-12-08 EP EP09164341A patent/EP2145958B1/en not_active Expired - Lifetime
- 1997-12-08 EP EP06125424A patent/EP1806360A3/en not_active Ceased
- 1997-12-08 DE DE69739220T patent/DE69739220D1/de not_active Expired - Lifetime
- 1997-12-08 EP EP10184082A patent/EP2287309A1/en not_active Withdrawn
- 1997-12-08 CN CNB971816743A patent/CN1221662C/zh not_active Expired - Fee Related
- 1997-12-08 AT AT97954089T patent/ATE420956T1/de not_active IP Right Cessation
- 1997-12-08 PT PT97954089T patent/PT948614E/pt unknown
- 1997-12-08 AT AT09164341T patent/ATE547524T1/de active
- 1997-12-08 CA CA2707726A patent/CA2707726C/en not_active Expired - Fee Related
-
1999
- 1999-06-02 IL IL130247A patent/IL130247A/en not_active IP Right Cessation
- 1999-06-07 NO NO19992756A patent/NO327411B1/no not_active IP Right Cessation
-
2004
- 2004-12-17 US US11/015,117 patent/US7524944B2/en not_active Expired - Fee Related
-
2006
- 2006-09-26 IL IL178306A patent/IL178306A0/en not_active IP Right Cessation
-
2007
- 2007-09-27 NO NO20074906A patent/NO331434B1/no not_active IP Right Cessation
-
2009
- 2009-02-13 US US12/371,188 patent/US7906638B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0948614T3 (da) | Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme | |
| PT662137E (pt) | Transcricao de genes e radiacao ionizante: metodos e composicoes | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| IL190793A0 (en) | A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain | |
| ATE407949T1 (de) | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen | |
| DK1240337T3 (da) | Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser | |
| ATE380195T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| HUP0002095A2 (hu) | Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk | |
| ATE437232T1 (de) | Rekombinanter adenoviren-vektor und verfahren zur verwendung | |
| DE69707985D1 (de) | Kodierende sequenzen des menschlichen brca1-gens | |
| DE19975064I1 (de) | Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, daf}r kodierende DNS und diese DNS verwendendes Testfahren. | |
| DE69940964D1 (de) | Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums | |
| BG103149A (en) | Npr genes for acquired resistance and their application | |
| ATE411392T1 (de) | Pockenviren mit zielgerichteter infektionsspezifität | |
| ATE481986T1 (de) | Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie | |
| ATE307886T1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| DK1390403T3 (da) | Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf | |
| DK1368054T3 (da) | Anvendelse af neurale trådproteiner til behandling af tumorer | |
| EP1100815A4 (en) | PROTEASE TYPE II CLEAVABLE PEPTIDE | |
| MXPA03000979A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
| ATE517122T1 (de) | Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren | |
| ATE290394T1 (de) | Verwendung von adenoassoziierten viren zur senkung der radio- oder chemotherapieinduzierten resistenz bei krebspatienten | |
| ATE516364T1 (de) | Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5 | |
| ATE105335T1 (de) | Traegergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine. |